AIMC Topic: Ventricular Dysfunction, Left

Clear Filters Showing 41 to 50 of 83 articles

Validation of a deep-learning semantic segmentation approach to fully automate MRI-based left-ventricular deformation analysis in cardiotoxicity.

The British journal of radiology
OBJECTIVE: Left-ventricular (LV) strain measurements with the Displacement Encoding with Stimulated Echoes (DENSE) MRI sequence provide accurate estimates of cardiotoxicity damage related to chemotherapy for breast cancer. This study investigated an ...

A method to screen left ventricular dysfunction through ECG based on convolutional neural network.

Journal of cardiovascular electrophysiology
OBJECTIVE: This study aims to develop an artificial intelligence-based method to screen patients with left ventricular ejection fraction (LVEF) of 50% or lesser using electrocardiogram (ECG) data alone.

External validation of a deep learning electrocardiogram algorithm to detect ventricular dysfunction.

International journal of cardiology
OBJECTIVE: To validate a novel artificial-intelligence electrocardiogram algorithm (AI-ECG) to detect left ventricular systolic dysfunction (LVSD) in an external population.

Left ventricular systolic dysfunction identification using artificial intelligence-augmented electrocardiogram in cardiac intensive care unit patients.

International journal of cardiology
BACKGROUND: An artificial intelligence-augmented electrocardiogram (AI-ECG) can identify left ventricular systolic dysfunction (LVSD). We examined the accuracy of AI ECG for identification of LVSD (defined as LVEF ≤40% by transthoracic echocardiogram...

Artificial Intelligence ECG to Detect Left Ventricular Dysfunction in COVID-19: A Case Series.

Mayo Clinic proceedings
Coronavirus disease 2019 (COVID-19) can result in deterioration of cardiac function, which is associated with high mortality. A simple point-of-care diagnostic test to screen for ventricular dysfunction would be clinically useful to guide management....

The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
BACKGROUND: Sacubitril/valsartan, the first agent to be approved in a new class of drugs called angiotensin receptor neprilysin inhibitors (ARNIs), has been shown to reduce cardiovascular mortality and morbidity compared to enalapril in outpatient su...